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Background: The local invasion of tumor cells into the surrounding tissue is the first and most critical step of the
metastatic cascade. Cells can invade either collectively, or individually. Individual cancer cell invasion can occur in
the mesenchymal or amoeboid mode, which are mutually interchangeable. This plasticity of individual cancer cell
invasiveness may represent an escape mechanism for invading cancer cells from anti-metastatic treatment.
Methods: To identify new signaling proteins involved in the plasticity of cancer cell invasiveness, we performed
proteomic analysis of the amoeboid to mesenchymal transition with A375m2 melanoma cells in a 3D Matrigel matrix.
Results: In this screen we identified PKCα as an important protein for the maintenance of amoeboid morphology.
We found that the activation of PKCα resulted in the mesenchymal-amoeboid transition of mesenchymal K2 and
MDA-MB-231 cell lines. Consistently, PKCα inhibition led to the amoeboid-mesenchymal transition of amoeboid
A375m2 cells. Next, we showed that PKCα inhibition resulted in a considerable decrease in the invading abilities
of all analyzed cancer cell lines.
Conclusions: Our results suggest that PKCα is an important protein for maintenance of the amoeboid
morphology of cancer cells, and that downregulation of PKCα results in the amoeboid to mesenchymal transition.
Our data also suggest that PKCα is important for both mesenchymal and amoeboid invasiveness, making it an
attractive target for anti-metastatic therapies.
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The ability to form metastases is the most dangerous
property that tumor cells can acquire. Cells of a primary
tumor can disseminate throughout the body and poten-
tially establish secondary tumors – metastases - in a
process called the metastatic cascade (reviewed in [1]).
The local invasion of tumor cells into the surrounding
tissue is the first and most critical step of the metastatic
cascade, and importantly, it determines the metastatic
potential of many tumor cell types. Cells can invade
through tissue and the extracellular matrix (ECM) either
collectively, or individually. During collective invasion,
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unless otherwise stated.sheets or irregular masses [2-4]. Individual invasion is
the invasion of single cells and can occur in mesenchymal
or amoeboid mode (reviewed in [5,6]). The mesenchymal
mode of invasion can be recognized by the typical
fibroblast-like morphology of individually-invading cancer
cells and also by their polarized character. At the leading
edge, the cells generate actin rich structures, filopodia and
lamellipodia, that trigger the cancer cell movement. For-
mation of filopodia and lamellipodia is regulated by the
small GTPases Rac1 and Cdc42 [7,8]. Mesenchymal in-
vasion is also dependent on local degradation of the
ECM by degrading enzymes. The secretion of proteo-
lytic enzymes is localized in actin-rich adhesion struc-
tures called invadopodia [9].
The morphology of amoeboid cells is typically round or
ellipsoid in a 3D environment. Amoeboid cancer cell inva-
sion is mediated by the contractions of cortical actin,
which is regulated by the Rho/ROCK signaling pathway.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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activate ROCK kinase. ROCK kinase phosphorylates
MLCP (myosin light chain phosphatase) to inhibit its
phosphatase function towards the myosin light chain
(MLC), and ROCK therefore increases MLC [10-12]. To
promote the effect, MLC2 is also directly phosphory-
lated by ROCK kinase. The phosphorylation of MLC
leads to the generation of higher contractile forces by
the actomyosin cortex, thus allowing the migration of
cancer cells through ECM fibers independently of pro-
teolytic degradation [13,14].
Cancer cell invasion is a very complex and plastic
process, and the mesenchymal and amoeboid modes of
invasion are mutually interchangeable. Activation or in-
hibition of specific signaling cascades leading to a spe-
cific mode of invasion can cause a switch from one
invasion mode to another (reviewed in [5,6,15,16]). It has
been demonstrated that the mesenchymal-amoeboid tran-
sition (MAT) may be an escape mechanism in tumor cell
invasion after the abolition of pericellular proteolysis [17].
The mechanisms of MAT or the amoeboid-mesenchymal
transition (AMT) are, however, poorly understood. Only a
limited number of studies describing the molecular mech-
anisms underlying MAT/AMT have been published so far
(reviewed in [6]). In order to better understand the plasti-
city of individual cancer cell invasion, it is critical to iden-
tify other proteins involved in MATand/or AMT.
To identify new signaling proteins involved in MAT/
AMT, we performed proteomic analysis of AMT with
melanoma cells cultured in a 3D Matrigel matrix. Pro-
tein microarrays were chosen instead of gene expression
microarrays because AMT and MAT are highly dynamic
processes and thus are mostly defined by changes in
posttranslational modifications of proteins and not in
mRNA expression levels. To our knowledge, this is the
first proteomic study of this kind performed with cells in
a 3D matrix. We identified PKCα as a protein important
in the amoeboid mode of cancer cell invasion. Next,
using biochemical and genetic approaches, we confirmed
the role of PKCα in regulating cancer cell morphology,
the effectiveness of cancer cell invasiveness, and overall
cancer cell plasticity.
Methods
Cells, culture and material
A375m2 melanoma cells were cultivated in full DMEM
medium: DMEM (GIBCO) with 4500 mg/l L-glucose,
L-glutamine, and pyruvate, supplemented with 10% fetal
bovine serum (Sigma), 2% antibiotic-antimycotic (GIBCO)
and 1% MEM non-essential amino acids (GIBCO). MDA-
MB-231 breast cancer cells were maintained in full RPMI
medium: RPMI (Gibco) supplemented with 10% fetal bo-
vine serum (Sigma), 2% antibiotic-antimycotic (GIBCO)
and 1% MEM non-essential amino acids (GIBCO). K2sarcoma cells were cultivated in in MEM with Hanks’ salts
supplemented with 10% bovine serum (ZVOS), 0.09% so-
dium bicarbonate, 0.12 g/L sodium pyruvate, and 1 mmol/
L glutamine. All cell lines were kept at 37°C in a humidi-
fied atmosphere with 5% CO2. Gö6976 – PKCα and PKCβ
inhibitor, and PMA (phorbol 12-myristate 13-acetate) –
PKC activator were used at concentrations of 1 μM and
162nM, respectively.
DNA and RNA constructs and transfection
Flag-tagged wt PKCα, constitutive active form (with myr-
istoylation sequence from Src) and dominant-negative
PKCα (K368R) in pCMV6 vector were all obtained from
Addgene Inc. Silencer® Select Validated siRNA against
PKCα was obtained from Applied Biosystems and a final
concentration of 10 nM was used for transfections. All
transfections were performed using jetPRIME™ transfec-
tion kits (Polyplus Transfection) according to the manu-
facturer’s instructions.
Immunoblotting
For 2D lysates, cells were cultured on plates with or
without Y 27632 for 48 hours. then washed with phos-
phate buffered saline (PBS) and lysed in modified RIPA
buffer (0.15 M NaCl; 50 mM Tris HCl (pH 7.4); 1%
Nonidet P 40; 0.1% SDS; 1% sodium deoxycholate;
5 mM EDTA; 50 mM NaF ).
For 3D lysates, cells were first embedded into 500 μl of
Matrigel solution (BD, MatrigelTM Basement Membrane
Matrix Phenol Red Free) with or without Y 27632. After
24 hours, Matrigel was solubilized using Cell Recovery
Solution (BD) for 30 min at 4°C. Cells were washed with
PBS and lysed in RIPA buffer.
Protein concentrations in the lysates were determined
using the DC Protein Assay (Bio Rad). Protein lysates were
diluted in Laemmli sample buffer (0.35 M Tris HCl,
pH 6.8; 10% SDS; 40% glycerol; 0.012% bromphenol blue).
For immunoblotting, samples were separated on 10% SDS
polyacrylamide gels and transferred onto nitrocellulose
membranes. Nonspecific activity was blocked by incubat-
ing membranes for 1 h at 37°C in Tris buffered saline con-
taining 4% bovine serum albumin. Membranes were then
incubated overnight at 4°C with primary antibody, washed
extensively with TTBS, and then incubated for 1 h at room
temperature with HRP conjugated secondary antibody.
After extensive washing in TTBS, the blots were devel-
oped using the LAS 1000 Single System (Leica). Monoclo-
nal antibodies against FLAG anti-FLAG (F3165) and total
PKCα (P 4334) were from Sigma Aldrich Inc., PKCα
pSer657 (sc-12356) and actin (sc 1616) were from Santa
Cruz Biotechnology Inc., β-catenin antibody (610154) was
from BD Transduction laboratories, p-cofilin Ser3 anti-
body (clone 77G2) was from Cell Signaling Technology.
Secondary Antibodies GAR-HRP polyclonal (sc 2030) and
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Biotechnology Inc., and GAM-HRP polyclonal (35502)
was from Thermo Fisher Scientific Inc.
Protein microarrays
2.4×106 cells were embedded into 8 ml of Matrigel (BD,
MatrigelTM Basement Membrane Matrix Phenol Red
Free) in the presence or absence of 50 μM Y 27632. After
24 hours of incubation the Matrigel was solubilized with
Cell Recovery Solution (BD) for 30 min at 4°C. Cells
were sedimented by centrifugation, washed in PBS and
sent for analysis by Kinexus Bioinformatics Corporation
(EXPANDED KINEX™ 800 ANTIBODY MICROARRAY
SERVICE) on dry ice to determine changes in the expres-
sion and/or phosphorylation status of selected signaling
proteins. Two experiments were performed in duplicates.
Cell morphology assays in 3D collagen
To analyze cell morphology of whole cell population in
3D collagen (in invasion assays only 10% of cells reach
deeper layers of 3D collagen), cells were trypsinized,
washed in complete medium, counted, and then 105
cells were mixed with 500 μl of 3 mg/ml Collagen R
(Serva) in complete medium. This suspension of cells in
collagen (500 μl) was loaded into a well of a 24-well
plate, the gel was allowed to polymerize at 37°C for
30 min, and was then overlaid with complete medium.
After 24 hours, the morphology of cells in 3D collagen
was analyzed using a Nikon Eclipse TE2000-S micro-
scope (20×/0,40 HMC objective). Morphology of each
cell was determined to be either elongated, intermediate
or round. This was done on the basis of an elongation
index. Elongation index was calculated as the length of
the cell divided by the width. Cells whose elongation
index was greater than 2 were considered elongated.
Intermediate cells had an elongation index of 1,5-2; for
rounded cells, the index was 1-1,5. Dividing cells were
excluded from the analysis. Proportion of elongated,
intermediate and rounded cells was calculated and
expressed percentually. Three independent experiments
(at least 300 cells per experiment) were analyzed for
each condition. As the data have the form of counts in
categories, the Pearson’s Chi-squared test was used to
reveal statistically significant differences.
In vitro cell invasion assays in 3D collagen
The 3D collagen invasion assay was analyzed as described
previously [18]. Briefly, cell suspension (1 × 105 cells/ml)
was added on top of a collagen gel in a multiwell plate (μ-
Slide Angiogenesis ibiTreat Microscopy Chamber (IBIDI)),
and after 48 hours the level of invasion was measured. Pic-
tures of 3D collagen cross-sections in the selected view
were taken every 10 μm using a Nikon-Eclipse TE2000-S
(20×/0.40 HMC objective) and NIS-Elements software.For each experiment, invasion was analyzed in 3 wells and
average invasion depth was assessed in 6 fields of view per
individual well. In order to compare individual experi-
ments, the average invasion depth was normalized to that
of untreated cells. In average the depth of at least 10 um
was achieved by 43 percent of K2 cells, 50 percent of
MDA-MB-231 cells and 60 percent of A375m2 cells.
Three independent experiments were analyzed for each
condition. The significance of differences was analyzed
with ANOVA followed by Tukey’s honest significant dif-
ference test. The analysis was performed in R [19].
Gelatin degradation assay
Dry coverslips were coated with a thin layer of FITC-
conjugated gelatin and immediately overturned on a
drop of 0.5% ice-cold glutaraldehyde in PBS for 15 min
incubation in the dark. Coverslips were then transferred
to a 12-well plate, with the coated side up and gently
washed three times with PBS, incubated with sodium
borohydride (5 mg/ml) in PBS for 3 min and then finally
washed with PBS. The cover slips were sterilized in 70%
ethanol for 1 min, dried for 10 min in a sterile hood and
quenched in complete medium for 1 h at 37°C. 48 hours
after transfection, cells were plated onto prepared FITC-
labeled gelatin-coated coverslips. Overnight, cells were
allowed to adhere and degrade gelatin and next day, cells
were fixed and stained for actin. For actin staining, fluo-
rescently labeled phalloidin (Alexa Fluor® 405 phalloidin
(Invitrogen)) was used. Finally, coverslips were mounted
on a mounting slide. Images for gelatin degradation assay
were taken by fluorescent microscope Nikon Eclipse
TE2000-S using (20×/0.40 HMC objective). Seven random
fields were analyzed in each experiment using AnalyzeGel-
Stack software (obtained from Prof. R. Buccione). Using
this software, degradation area normalized to the number
and area of cells (degradation area per cell) was measured.
Values were normalized to value of control untreated cells.
Confocal microscope Leica DM IRE2 was used for better
cell visualization and taking representative pictures.
Cell viability assay
Cell viability was assessed by the trypan blue dye exclusion
method. Briefly, cells were seeded into two 3.5 mm dishes,
the next day 1 μM Gö6976 was added to one of the dishes.
After 48 hours cells were trypsinized and diluted 1:1 in
0.4% sterile filtered trypan blue solution. The cells were in-
cubated in the trypan blue solution for 5 minutes at room
temperature and then transferred onto a haemocytometer
and counted under a light microscope. Viable cells ap-
peared bright, dead cells were blue. Three independent ex-
periments were performed, each time both sides of the
haemocytometer were counted twice for both conditions.
To assess the statistical significance of the differences, the
Pearson’s Chi-squared test was performed.
Table 1 Proteins with differential expression/
phosphorylation after AMT in A375m2 cells (Kinexus)
Protein Phosphosite (human) Refseq Fold change
IKK alpha Pan-specific NP_001269 6.7
CDK7 Pan-specific NP_001790 5.2
ASK1 (MAP3K5) Pan-specific NP_005914 3.2
STAT1a/b Pan-specific NP_009330 3.2
Catenin beta Pan-specific NP_001895 2.4
MEK6 (MAP2K6) S207 NP_002749 2.3
Erk2 Pan-specific NP_002736 2.3
Cofilin 2 S3 NP_068733 2.3
CASP4 Pan-specific NP_001216 2.1
Hsp90 Pan-specific NP_005339 -26.4
JNK1/2/3 Pan-specific NP_002741 -22.6
Bid Pan-specific NP_001187 -15.2
CDK1 (CDC2) Pan-specific NP_001777 -9.6
PERP Pan-specific NP_071404 -8.7
Hsc70 Pan-specific NP_006588 -6.1
JNK2 Pan-specific NP_002744 -5.2
APG1 Pan-specific NP_055093 -5.0
PDK1 Pan-specific NP_002604 -4.3
HO1 Pan-specific NP_002124 -3.8
PLC gamma 1 Y783 NP_877963.1 -3.6
CaMK1d Pan-specific NP_003647 -3.5
MEK4 (MAP2K4) Pan-specific NP_003001 -3.3
PKC alpha S657 NP_002728 -3.2
IRAK2 Pan-specific NP_001561 -3.2
Mnk2 Pan-specific NP_060042 -3.1
p35 Pan-specific NP_003876 -3.0
FAK Y577 NP_005598 -3.0
BRCA1 S1497 NP_009225 -3.0
BRCA1 S1423 NP_009225 -2.9
4E-BP1 T45 NP_004086 -2.6
Bak Pan-specific NP_001179 -2.5
MEK1 (MAP2K1) T385 NP_002746 -2.5
MEK5 (MAP2K5) Pan-specific NP_660143 -2.4
TrkA Pan-specific NP_002520 -2.4
Pax2 S394 NP_000269.2 -2.4
STAT3 Pan-specific NP_003141 -2.3
MEK7 (MAP2K7) Pan-specific NP_005034 -2.3
PKC epsilon S729 NP_005391 -2.3
PKBb (Akt2) Pan-specific NP_001617 -2.1
GCK Pan-specific NP_004570 -2.1
p38a MAPK Pan-specific NP_001306 -2.1
Antibody microarray (Kinex) screen of A375m2 cells in AMT. Cells in 3D culture
were treated with ROCK inhibitor and analyzed after 24 hours. Signal values
from duplicate samples were tested for significant differences with Student’s
t-test followed by p-value correction for multiple testing (Benjamini-Hochberg).
Proteins that showed at least two-fold change and FDR < 0.3 are shown here,
complete data are available in supplementary information. Proteins discussed
in the text are in boldface.
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Protein microarray analysis reveals the down-regulation
of PKCα phosphorylation in highly metastatic amoeboid
A375m2 melanoma cells after AMT
To identify new proteins involved in amoeboid invasive-
ness and the AMT, we analyzed proteomic profiles of
cells before and after AMT. We used amoeboid melan-
oma A375m2 cells that were cultivated in 3D Matrigel
and either induced AMT with the ROCK kinase inhibi-
tor Y-27632 or left the cells untreated. We observed
100% rounded A375m2 cells in Matrigel before addition
of Y-27632. After the Y-27632 the number of rounded
cells was decreased to 43%. 31% were elongated and 26%
exhibited intermediate morphology (see also Additional
file 1: Figure S1). Cell lysates from both untreated and
treated cells were analyzed using protein microarray ana-
lysis (Kinex). 30 proteins showed significant changes in ex-
pression levels between cells cultivated without and with
Y-27632. Moreover, 11 proteins exhibited significant
changes in the phosphorylation of analyzed sites (Table 1).
Among these proteins, we selected several candidates with
potential connections to AMT-related signaling for further
verification. These included β-catenin (increased expres-
sion after AMT), cofilin-2 (increase Ser3 phosphorylation
after AMT) and PKCα (decreased Ser657 phosphorylation
after AMT). For all the three selected proteins we con-
firmed the trends in changes of their phosphorylation
(cofilin-2, PKCα) or expression (β-catenin) status after
AMT (Figure 1). Interestingly, the changes were only
seen when Y-27632 was administered in the 3D Matrigel
and not in 2D conditions (Figure 1), suggesting that these
changes are in fact specific for AMT. Since we were most
interested in proteins with potential involvement in
amoeboid invasiveness, in our next experiments we con-
centrated on PKCα which was found to be down-
regulated after AMT.
Inhibition of PKCα results in AMT in amoeboid cells,
PKC activation results in MAT in mesenchymal cells
The phosphorylation of PKCα at Ser657 is associated with
increased stability of the kinase [20,21]. Our protein micro-
array analysis thus suggests that PKCα activation could
possibly be involved in maintenance of the amoeboid
morphology of melanoma A375m2 cells. To investigate the
possible role of PKCα in regulating cell morphology, we
analyzed the morphology of selected mesenchymal and
amoeboid cell lines in 3D collagen in the presence and ab-
sence of a PKCα activator or inhibitor. The A375m2 hu-
man melanoma cell line, K2 rat sarcoma cell line and
MDA-MB-231 human breast cancer cell line were used.
Cells were seeded into 3D collagen matrix and the morph-
ology of cells was observed after 48 hours of incubation.
As a PKCα activator, phorbol 12-myristate 13-acetate
(PMA) was used at a final concentration of 162nM. PMA
Figure 1 Proteins with differential expression/phosphorylation after
AMT in A375m2 cells (Kinexus). Phosphorylation of cofilin2 at Ser3,
expression of β-catenin, phosphorylation of PKCα at Ser657 and
expression of PKCα were detected using corresponding antibodies
in cell lysates from A375m2 strain upon AMT (induced by ROCK
kinase inhibitor Y37632) both in 3D and 2D environment. Representative
immunoblots are shown. Densitometric analysis was made using ImageJ
software. Quantification was made from three independent experiments
and normalized to that of untreated cells.
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PKC isoforms. As a PKCα inhibitor, Gö6976 was used at a
1 μM concentration. Gö6976 is a PKCα/PKCβ specific in-
hibitor. However, proteomic analysis did not show any
changes in other PKC isoforms than PKCα, so the activator
and particularly the inhibitor were considered to be suffi-
ciently specific for our experiments.
Analysis of the cellular morphology in 3D collagen
confirmed that A375m2 cells are primarily amoeboid
(rounded cell morphology) and K2 and MDA-MB-231
cells are primarily mesenchymal (elongated cell morph-
ology) (Figure 2, Additional file 2: Figure S2). Upon
PMA treatment, the morphology of K2 and MDA-MB-
231 cells shifted from mesenchymal towards amoeboid.
For K2 cells, the proportion of rounded cells was in-
creased approximately 4 fold, and for MDA-MB-231
cells a 3 fold increase was observed (Figure 2, Additional
file 2: Figure S2). In both cases, the number of elongated
cells decreased proportionally. This strongly suggests the
occurrence of the MAT. PMA did not have a significant
effect on A375m2 cells as these cells were already of
predominantly rounded morphology. In contrast, treat-
ment with the PKCα inhibitor Gö6976 resulted in the
AMT of A375m2 cells, manifested by a 2.5 fold increase
in the proportion of elongated cells. Simultaneously, the
proportion of rounded cells decreased. Gö6976 did not
greatly affect the morphology of K2 and MDA-MB-231
cells as these cells were already of mainly elongated
morphology (Figure 2, Additional file 3: Figure S3).Inhibition of PKCα results in decreased cancer cell
invasiveness
Next, the invasivity of cells in vitro was analyzed to de-
termine the effect of PKCα on the capacity of cells to in-
vade 3D collagen. Incubation of cells with the PKC
activator PMA did not significantly change the cell inva-
sion potential of any of the three cell lines examined. In
contrast, treatment with the PKCα/β inhibitor Gö6976
resulted in a mild but significant decrease in the inva-
siveness of all three cell lines (Figure 3). This decrease
was 1.3 fold in the case of K2 cells, 1.5 fold in the case
of MDA-MB-231 cells, and 1.4 fold in the case of
A375m2 cells. To exclude the possibility that the de-
creased invasiveness is caused by cytotoxic effect of PKC
alpha inhibition, we have analyzed the effect of Gö6976 on
cell survival of MDA-MB-231 cells. We found no signifi-
cant effect of the inhibitor at the concentration used in
our assays (1.7% and 3.3% dead cells in control and treated
cells, respectively with chi-squared test p-value 0.197).
Overexpression or activation of PKCα promotes MAT in
mesenchymal cells, dominant-negative PKCα promotes
AMT in amoeboid cells
To further confirm the role of PKCα in amoeboid inva-
siveness and AMT/MAT we decided to validate the ef-
fects of the PKC inhibitor and activator using a genetic
approach. In all three cell lines we overexpressed wt
PKCα or dominant-negative PKCα (K368R) to achieve
activation and inhibition of PKCα, respectively. In trans-
fected cells, the expression of each PKCα variant was
demonstrated using an immunoblot (Additional file 3:
Figure S3A). Surprisingly, the expression of dominant-
negative PKCα was much lower than that of wt PKCα,
possibly due to negative selection. The activation status
of the variants was verified with a phospho-specific anti-
body against Thr497 in the activation loop of PKCα
(Additional file 3: Figure S3A).
To verify the possible role of PKCα in regulating
AMT/MAT, we performed morphology assays in 3D col-
lagen with the A375m2 human melanoma cell line, K2
rat sarcoma cell line and MDA-MB-231 human breast
cancer cell line transfected with PKCα variants. Upon
the overexpression of wt PKCα, K2 and MDA-MB-231
cells changed their morphology towards amoeboid. For
both cell lines, the proportion of rounded cells was in-
creased approximately 1.7 fold (Figure 4, Additional file 4:
Figure S4) and the number of elongated cells decreased
proportionally. This strongly suggests the occurrence of
MAT. The expression of wt PKCα did not have significant
effect on A375m2 cells as these cells were already of pre-
dominantly rounded morphology. In contrast, the expres-
sion of dominant-negative PKCα resulted in the AMT of
A375m2 cells, manifested by a 2 fold increase in the pro-
portion of elongated cells. Simultaneously, the proportion
Figure 2 Inhibition of PKCα results in AMT in amoeboid cells, PKC activation results in MAT in mesenchymal cells. Cell morphology analysis of
A375m2 (A), K2 (B) and MDA-MB-231 (C) strains upon PKC activator PMA or PKCα/β inhibitor Gö6976 treatment. Cells were incubated with PMA
(162nM) or Gö6976 (1 μM) for 48 hours in 3D collagen and then analyzed using NIS Elements software (Nikon). Cells were classified according to
the elongation index as rounded, intermediate or elongated (see Methods section). Statistical significance (marked by asterisks) was evaluated
using Pearson’s Chi-squared test. Representative results are shown out of minimum three independent experiments.
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negative PKCα did not greatly affect the morphology of
K2 and MDA-MB-231 cells as these cells were already of
mainly elongated morphology (Figure 4, Additional file 4:
Figure S4).
Expression of dominant-negative PKCα results in
decreased cancer cell invasiveness
Next, the invasivity of cells in vitro was analyzed to deter-
mine the effect of PKCα variants on the capacity of cells
to invade 3D collagen. Again, K2, A375m2 and MDA-
MB-231 cell lines transfected with wt or dominant-
negative PKCα were used. The expression of wt PKCα
resulted in a slight, but not significant decrease of invasive-
ness in mesenchymal cell lines and also a non-significant
increase of invasiveness in amoeboid A375m2 cells. MoreFigure 3 Inhibition of PKCα results in decreased invasiveness of cancer cel
upon PKC activator PMA or PKCα/β inhibitor Gö6976 treatment. Cells were
presence of PMA (162nM) or Gö6976 (1 μM). 3D collagen cross-sections were
was calculated and normalized to that of untreated cells. The invasion depth
individual cells divided by the total number of cells in the respective field of v
by asterisks) was evaluated using ANOVA followed by Tukey’s honest significaimportantly, the expression of dominant-negative PKCα re-
sulted in a significant decrease of invasiveness in all investi-
gated cancer cell lines (Figure 5). These results suggest that
PKCα is important for effective cancer cell invasiveness
irrespective of the type of cancer cell invasion.
siRNA-mediated downregulation of PKCα results in AMT
in A375m2 amoeboid cells
To further confirm the specific effect of PKCα isoform
on the cell morphology and invasiveness of amoeboid
cancer cells, specific downregulation of PKCα expression
in A375m2 cells was performed using siRNA against
PKCα. In comparison to control and mock-transfected
cells, total PKCα expression level in siRNA treated cells
was significantly lower (Additional file 3: Figure S3B). In
agreement with the effect of the PKCα inhibitor andls. Invasion analysis of A375m2 (A), K2 (B) and MDA-MB-231 (C) strains
plated onto 3D collagen and let to invade it for 48 hours in the
analyzed using NIS Elements software (Nikon) and average invasion depth
in each individual field of view was assessed as sum of invasion depths of
iew (including cells on the top of collagen). Statistical significance (marked
nt difference test.
Figure 4 Dominant-negative PKCα promotes AMT in amoeboid cells, overexpression of PKCα promotes MAT in mesenchymal cells. Cell
morphology analysis of A375m2 (A), K2 (B) and MDA-MB-231 (C) strains overexpressing wt PKCα or expressing dominant-negative PKCα. Cells
were transfected with pCMV6 vector expressing either wt PKCα or dominant-negative PKCα and their morphology was observed after 48 hours in
3D collagen. Cells were analyzed using NIS Elements software (Nikon). Cells were classified according to the elongation index as rounded, intermediate
or elongated (see Methods section). Statistical significance (marked by asterisk) was evaluated using Pearson’s Chi-squared test. Representative results
are shown out of minimum three independent experiments.
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cells exhibited a more mesenchymal morphology profile
than control and mock-transfected cells, suggesting the
induction of AMT. The proportion of elongated cells in-
creased 2 fold, and there was a minor increase in the
proportion of intermediate cells as well. Consistently,
the proportion of rounded cells decreased (Figure 6A,
Additional file 5: Figure S5). The amoeboid to mesenchy-
mal transition was also manifested by elevated ability of
siRNA treated A375m2 cells to degrade gelatin (Additional
file 6: Figure S6).
In vitro invasion analysis of siRNA transfected cells
showed that PKCα downregulation reduced the cell
invasivity of A375m2 cells in 3D collagen (Figure 6B).Figure 5 Expression of dominant-negative PKCα results in decreased invas
MDA-MB-231 (C) strains overexpressing wt PKCα or expressing dominant-n
either wt PKCα or dominant-negative PKCα and let to invade into 3D colla
Elements software (Nikon) and average invasion depth was calculated and
individual field of view was assessed as sum of invasion depths of individu
view (including cells on the top of collagen). Statistical significance (marked
significant difference test.Compared to mock-transfected cells, the ability of
siRNA treated cells to invade into 3D collagen was re-
duced 1.5 fold, and this reduction was even higher (2.5
fold) compared to untreated cells. This is consistent
with previous experiments where PKCα inhibition also
resulted in a significant decrease in cell invasion poten-
tial. Together, these results further confirm the import-
ant role of PKCα in amoeboid invasiveness.
Discussion
PKCα is a very important protein regulating many signal-
ing pathways in cells, such as proliferation, differentiation,
apoptosis and tumorigenesis (reviewed in [22]), and its de-
regulation is involved in many diseases (reviewed in [23]).iveness of cancer cells. Invasion analysis of A375m2 (A), K2 (B) and
egative PKCα. Cells were transfected with pCMV6 vector expressing
gen for 48 hours. 3D collagen cross-sections were analyzed using NIS
normalized to that of untreated cells. The invasion depth in each
al cells divided by the total number of cells in the respective field of
by asterisks) was evaluated using ANOVA followed by Tukey’s honest
Figure 6 siRNA-mediated downregulation of PKCα results in AMT in A375m2 amoeboid cells. A) Cell morphology analysis of A375m2 strain
transfected with siRNA against PKCα. Cells were transfected with siRNA and their morphology was observed after 48 hours in 3D collagen. Cells were
analyzed using NIS Elements software (Nikon). Cells were classified according to the elongation index as rounded, intermediate or elongated (see
Methods section). Statistical significance (marked by asterisk) was evaluated using Pearson’s Chi-squared test. Representative result is shown out of three
independent experiments. B) Cell invasion analysis of A375m2 strain transfected with siRNA against PKCα. Cells were transfected with siRNA and let to
invade into 3D collagen for 48 hours. 3D collagen cross-sections were analyzed using NIS Elements software (Nikon) and average invasion depth was
calculated and normalized to that of untreated cells The invasion depth in each individual field of view was assessed as sum of invasion depths of
individual cells divided by the total number of cells in the respective field of view (including cells on the top of collagen). Statistical significance
(marked by asterisks) was evaluated using ANOVA followed by Tukey’s honest significant difference test.
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and cancer cell invasion [24-29]. Proteomic analysis of
amoeboid A375m2 cells grown in 3D Matrigel revealed
that phosphorylation of PKCα at Ser657 is reduced
upon a ROCK kinase inhibitor Y-27632 mediated induc-
tion of AMT. Importantly, we found that the observed
changes in the phosphorylation of PKCα at Ser657 and
two additional candidate markers of AMT occur only in
3D Matrigel and not in 2D conditions. These results
confirm the necessity of performing AMT analyses in
the 3D environment.
In addition to decreased levels of PKCα phosphoryl-
ation at Ser657, the phosphoproteomics screen revealed
a significant decrease in the phosphorylation of a PKCα
upstream activator, PLCγ1 on Tyr783 (Table 1). This
suggests that treatment with the ROCK inhibitor Y-
27632 affects signaling leading to the activation of PKCα,
rather than directly inhibiting PKCα.
Ser657 is located in the hydrophobic region of PKCα
and its phosphorylation controls the accumulation of ac-
tive PKCα and prevents its down-regulation [20,21]. The
phosphoproteomics screen data thus suggested that by
affecting the level of PKCα activation we could induce
AMT or MAT in cancer cells. To confirm this, we ana-
lyzed the effect of PKCα inhibition and activation on the
morphology of amoeboid A375m2 and two mesenchy-
mal K2 and MDA-MB-231 cell lines. This morphology
analysis revealed that the level of PKCα activation is in-
deed important for the regulation of cell morphology in
the 3D environment. PKCα activation resulted in MAT
in both mesenchymal cell lines tested and, correspond-
ingly, PKCα inhibition or downregulation resulted in
AMT in amoeboid A375m2 cells.Next, in vitro invasivity assays into 3D collagen were
performed to elucidate the effect of PKCα directly on
cell invasiveness. Although PKCα activation did not sig-
nificantly influence the invasivity of cells, PKCα inhib-
ition resulted in a considerable decrease in the invading
abilities of all three cell lines used (K2, A375m2 and
MDA-MB-231). These results suggest that a proper level
of PKCα activation is necessary for effective invasiveness
of both amoeboid and mesenchymal cancer cell lines.
This is consistent with previous results that have shown
that PKCα regulates cell invasion and migration in sev-
eral cancer cell lines. Inhibition of PKCα has decreased
the invasion of urinary bladder carcinoma [30], colon
carcinoma [31], renal cell carcinoma [32], breast carcin-
oma [33], multiple myeloma [34], glioma [35], breast
cancer [36] and endometrial cancer cells [37]. PKCα ac-
tivation and overexpression have been shown to increase
cancer cell migration [31,33,34,36]. Consistently, PKCα
knockdown leads to a decrease in cancer cell invasion
[31,36,37]. Remarkably, PKCα was shown to be a marker
of aggressiveness in breast cancer, as patients with
PKCα-positive tumors exhibited poorer prognosis than
patients with PKCα-negative tumors [36].
Since PKC alpha was shown to be involved in cancer
cell survival (e.g. [38]), we had to rule out the possibility
the observed decrease of invasiveness could be at least
in part caused by a weak cytotoxic effect of PKCα inhib-
ition. We found that under our conditions, PKCα inhib-
ition does not have detectable cytotoxic effect.
Interestingly, the PKCα overexpression resulted in pos-
sibly decreased invasion (but not significant) in mesenchy-
mal cell lines and increased invasion (also not significant)
in amoeboid cell line, suggesting that for mesenchymal
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optimal and further increase of PKCα expression may not
result in increased invasion capability. Also it has to be
taken into account that amoeboid migration is faster par-
ticularly under non-restrictive conditions [39]. In dense
3D collagen gels the size of the pores is limiting for non-
proteolytic migration and under such conditions, tunnels
formed by the mesenchymal cells could be a more effect-
ive strategy, especially in cells which are originally mesen-
chymal (K2) or intermediate (MDA-MB-231).
Together, these results suggest a possible role of PKCα
in the amoeboid invasion of cancer cells. The setup of
our proteomic screen and the effects of PKCα activity
on amoeboid cancer cells suggest that PKCα might acti-
vate the small GTPase RhoA or ROCK kinase. The Rho/
ROCK signaling pathway controls phosphorylation of
the myosin light chain and mediates the enhanced acto-
myosin contractility that is a critical feature of amoeboid
cells [10,11,14]. However, it is likely that PKCα does not
phosphorylate RhoA or ROCK directly; rather, PKCα
might phosphorylate their upstream regulators.
Indeed, there is evidence in the literature of PKCα
regulating the Rho/ROCK signaling pathway through
upstream regulators, together with their relevance to cell
adhesion and cytoskeletal reorganization. Earlier results
showed that PKCα can be activated upon thrombin
treatment and can enhance RhoA activity in endothelial
cells, therefore mediating cell contraction [40,41]. PKCα
phosphorylates p115RhoGEF, a specific Rho guanine nu-
cleotide exchange factor, and increases its activity [42].
Consequently, RhoA activity is also increased and this is
connected to the regulation of stress fiber formation and
cell contraction [42]. One of the PKCα substrates is also
RhoGDIα [43]. RhoGDIα is a cytosolic protein that binds
the GDP-bound small RhoGTPases RhoA, Rac1 and
Cdc42, and prevents them from the exchange of GDP to
GTP [44]. PKCα phosphorylates RhoGDIα at Ser34 to re-
duce its affinity for RhoA (but not for Rac1 or Cdc42)
[43]. So, RhoA can be activated by GTP binding and
downstream signaling is enhanced, as was observed by a
loss of focal adhesions [40]. Also, phosphatidylinositol
bisphosphate is needed for RhoGDIα phosphorylation by
PKCα; it is probably required for proper PKCα localization
and orientation in the membrane [43]. Moreover, αvβ3 in-
tegrin and syndecan4-mediated PKCα activation enhances
RhoA activity to form focal adhesions and maintain stress
fibers [45,46].
More recently, results that connect PKCα directly to
the regulation of Rho/ROCK signaling pathway were
published [47-51]. PKCα regulates the localization of the
small GTPase Rnd3 (also called RhoE) [47]. Rnd3 binds
to ROCK kinase and prevents its downstream signaling -
upon Rnd3 binding, phosphorylation of MLCP is inhib-
ited and formation of ROCK-induced stress fibers isdisturbed [48]. Moreover, Rnd3 competes with PDK1 for
binding to ROCK kinase and thus prevents its proper
localization to the plasma membrane [49]. PKCα phos-
phorylates Rnd3 and causes its translocation to internal
membranes [47]. Upon this altered localization, Rnd3 is
no longer able to inhibit the Rho/ROCK pathway, which is
subsequently enhanced [47]. Moreover, Raf kinase path-
way activation, which could be regulated by PKCα [50],
was shown to be associated with Rnd3 expression [51].
Interestingly, in this study we have seen increased
phosphorylation of cofilin on Ser-2 after ROCK inhib-
ition. The positive effect of Y-27632 on cofilin phosphor-
ylation was observed only in 3D suggesting that specific,
and for AMT indispensable, condition of cultivation in
3D is responsible for the effect. Cofilin phosphorylation is
regulated both by kinases (LIMK family) and phosphatases
(SSH family). The KINEX microarray, however, allows to
analyze only changes in expression and phosphorylation
levels of LIMK1. It is hard to assess which of the pathways
of cofilin phosphorylation is predominant in particular
cells. We can speculate that in our case cofilin phosphoryl-
ation could be promoted via Rac/PAK1/LIMK2 signaling.
In fact we see a mild (60%) increase in PAK1 expression.
This was not included in our results as the p Value (0,079)
did not meet our criteria for significance. Finally, though it
might be contra intuitive others have also shown that
Y27632 treatment can induce an increase in cofilin phos-
phorylation [52].
Conclusions
Our results show that PKCα is an important regulator of
the amoeboid morphology of cancer cells and its down-
regulation causes AMT. Furthermore, our data also indi-
cate that PKCα is involved in both mesenchymal and
amoeboid invasiveness, making it an attractive target for
anti-metastatic therapies.Additional files
Additional file 1: Figure S1. The effect of Y-27632 treatment on
morphology of A375 m2 melanoma cells. Cells were grown in 3D
collagen and after 24 h cell morphology was analyzed and documented
using photomicroscopy. Left panel: A375 m2 cells; right panel: A375 m2
cells treated with 10 μM Y-27632.
Additional file 2: Figure S2. The expression of PKC alpha variants
and the effectiveness of PKCα silencing. A) The expression of wt PKCα,
constitutively-active PKCα and dominant-negative PKCα in K2, MDA-MB-231
and A375m2 strains. Total PKCα and phosphorylation of PKCα at Thr497 were
detected using corresponding antibodies in cell lysates from each strain
expressing wt PKCα, constitutively-active PKCα and dominant-negative PKCα
from pCMV6 vector. Representative immunoblots of each variant are shown.
Actin was used as a loading control. B) The expression of total PKCα in
siRNA-transfected A375m2 cells. Total PKCα level was detected in lysates from
control cells (not transfected), mock cells (transfected only with transfection
reagents, without siRNA) and siRNA transfected cells (siRNA against PKCα).
Representative immunoblots are shown. Actin was used as a loading control.
Vaškovičová et al. BMC Cancer  (2015) 15:326 Page 10 of 11Additional file 3: Figure S3. The effect of PKCα activation with PMA
and PKCα inhibition with Gö6976 on morphology of cancer cells. The
effect of PKCα activation with PMA and PKCα inhibition with Gö6976
on morphology of cancer cells. Cells were grown in 3D collagen and
after 24 h cell morphology was analyzed and documented using
photomicroscopy. Top panels: K2 cells; middle panels: A375 m2 cells;
bottom panels: MDA-MB-231 cells. Left panels: control untreated cells;
medium panels: cells treated with 162 nM PMA; right panels: cells treated
with 1 μM Gö6976.
Additional file 4: Figure S4. The effect of PKCα variants expression on
morphology of cancer cells. Cells were grown in 3D collagen and after 24 h
cell morphology was analyzed and documented using photomicroscopy. Top
panels: K2 cells; middle panels: A375 m2 cells; bottom panels: MDA-MB-231
cells. Left panels: control cells; medium panels: cells overexpressing wt PKCα;
right panels: cells expressing dominant-negative version of PKCα.
Additional file 5: Figure S5. The effect of PKCα silencing on
morphology of A375 m2 melanoma cells. Cells were grown in 3D
collagen and after 24 h cell morphology was analyzed and documented
using photomicroscopy. Left panel: A375m2 cells; medium panel:
A375m2 cells treated with scrambled siRNA; right panel: A375m2 cells
treated with PKCα-specific siRNA.
Additional file 6: Figure S6. The effect of PKCα on gelatin degradation
by A375m2 cells. The effect of PKCα on matrix-degrading activity in A375M2
melanoma cells. (A) Cells were plated on fluorescent gelatin-coated
coverslips and subjected to gelatin degradation assay as described in section
“Methods”. Representative fields were documented by photomicroscopy.
Left panel: A375M2 cells; middle panel: A375M2 cells treated with scrambled
siRNA; right panel: A375M2 cells treated with PKCα -specific siRNA. Top
panel: F-actin staining; bottom panel: gelatin degradation. (B) The
quantification of matrix degrading activity was performed as described in
section “Methods”. Histogram bars represent mean relative degradation
obtained from 3 independent experiments and normalized to that of
untreated A375M2 cells, the error bars represents standard deviations.
Statistical significance was evaluated according to unpaired two-tailed
Student’s t-test. Significant difference (p < 0.01) in comparison to
mock-transfected cells is indicated by asterisks.Abbreviations
AMT: Amoeboid-mesenchymal transition; ECM: Extracellular matrix;
MAT: Mesenchymal-amoeboid transition; MLC: Myosin light chain;
MLCP: Myosin light chain phosphatase; PMA: Phorbol 12-myristate
13-acetate.
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